

CHRISTOPHER R. WILLIAMS, M.D.

CURRENT POSITION

Assistant Professor Department of Surgery, Division of Urology
University of Florida College of Medicine, Jacksonville

Work Address 653 West Eighth St.
Jacksonville, FL 32209
Phone: 904-244-7293
Fax: 904-244-7422

EDUCATION

National Institutes of Health, National Cancer Institute, Urologic Oncology Branch
Bethesda, Maryland
NCI/AFUD Clinical/Research Fellow, July 2003 – June 2005

University of Alabama-Birmingham
Birmingham, Alabama
Intern and Resident, Department of General Surgery, June 1997 – June 1999
Resident, Division of Urologic Surgery, July 1999 – June 2003

University of North Carolina School of Medicine
Chapel Hill, North Carolina
Doctor of Medicine, May 1997

University of North Carolina
Chapel Hill, North Carolina
B.S. in Biology with Minor in Chemistry, May 1993
John Motley Morehead Scholar

RESEARCH EXPERIENCE

National Institutes of Health
National Cancer Institute, Urologic Oncology Branch
NCI/AFUD Clinical/Research Fellow, July 2003 – June 2005
Focus: Heat Shock Protein-90 Inhibition in Urologic Malignancies
Mentors: Len Neckers, PhD, Senior Investigator, Urologic Oncology Branch
Marston Linehan, Senior Investigator and Chief, Urologic Oncology Branch

Basic science research in gene therapy
University of Alabama-Birmingham
July – December 2000
Focus: Molecular Chemotherapy/Radiation Therapy in Prostate Cancer
Mentors:
Donald J. Buchsbaum, Ph.D.
Professor and Director, Division of Radiation Biology
C. Ryan Miller, Ph.D.
Postdoctoral Fellow, Divisions of Radiation Biology and Neurosurgery

CHRISTOPHER R. WILLIAMS, M.D.

Current research

Clinical research:

1. University of Florida Studies of Proton Beam Radiation Therapy for Low, Intermediate, and High Risk Adenocarcinoma of the Prostate. Role: sub-investigator
2. Post-operative Pain in Patients with Use of Abdominal Binder after Major Abdominal Surgery. Role: sub-investigator

Basic Science research:

1. Intratumoral Injection of Hsp90 inhibition in prostate cancer. Role: principal investigator
2. Hsp90 inhibition in testicular teratoma. Role: principal investigator

AWARDS AND HONORS

- 2003 ·Pfizer Scholar in Urology Award
·American Journal of Urology Review Resident Correspondent Scholarship Award to attend the Southeastern Section of American Urological Association Meeting
- 2002 ·AUA/Praecis Gerald P. Murphy Scholar (For distinction in the study of Prostate Cancer)
- 2001 ·International Volunteers in Urology Traveling Resident Scholarship to Peru
·American Association for Cancer Research Minority Scholar Award in Cancer Research
·First Place - R. Frank Jones Resident's Forum; Urology Section, National Medical Association Meeting. Nashville, TN.

MEMBERSHIPS

American Urological Association, 1999 – present
Society of Urologic Oncology, 2003 - 2005
Southeastern Section of the American Urological Association, 1999 - 2003; 2005-present
Mid-Atlantic Section of the American Urological Association, 2003-2005
National Medical Association, 2000 – present
American Association for Cancer Research, Associate Member, 2001 – 2002, 2008

Content Reviewer: American Urological Association 2007 – present

Reviewer: Journal of Urology - 2008

PUBLICATIONS

Published Manuscripts

1. **Williams, C. R.**, Linehan, W.M., Tabios, R., and Neckers, L. Intratumoral injection of 17AAG decreases tumor size and expression of HSP90 client proteins in prostate cancer xenograft model. *J. Urol.*, 178(4): 1528, 2007.
2. Anai, S., Wludyka, P., Pendleton, J., **Williams, C.**, Nelms, L., Pettaway, C., and Rosser, C. Prostate cancer screening and detection in inner-city and underserved men. *JNMA*, 98(4): 515, 2006.

CHRISTOPHER R. WILLIAMS, M.D.

3. Gotlib, J., Berubé, C., Growney, J., Chen, C., George, T., **Williams, C.**, Kajiguchi, T., Ruan, J., Cohen, P., Arber, D., Lichy, J., Heinrich, M., Neckers, L., Galli, S., Gilliland, D., and Coutré, S. Activity of the Tyrosine Kinase Inhibitor PKC412 in a Patient with Mast Cell Leukemia with the *D816V KIT* Mutation. *Blood*, 106(8): 2865, 2005.
4. Grubb, R., Behari, A., Kim, C., **Williams, C.**, Linehan, W. and Coleman, J. Highlights from the Society of Urologic Oncology, 5th Annual Meeting, December 3-4, 2004, Bethesda, Maryland, United States of America. *J. Urol.*, 174(6):2330, 2005.
5. **Williams, C.R.** and Walther, M. Metastatic renal cell carcinoma versus pancreatic neuroendocrine tumor in von Hippel-Lindau disease: Treatment with Interleukin-2. *Scientific World Journal*, 5:9, 2005.
6. Diner, E.K., **Williams, C.R.**, Pinto, P.A., and Walther, M.M.: Metastatic renal cell carcinoma to contralateral ureter presenting as acute obstructive renal failure after radical nephrectomy. *Urology*, 65(5): 1001, 2005.
7. Coleman, J., Franks, M., Grubb, R., Wynberg, J., Lee, C., Behari, A., Kim, C., **Williams, C.**, and Linehan, W. Highlights from the Society of Urologic Oncology, 4th Annual Meeting, December 5-6, 2003. *J. Urol.*, 173:938, 2005.
8. **Williams, C.R.**: Summaries of prostate cancer abstract presentations, radical prostatectomy expert panel discussion, and AACU lecture from the 67th Annual Meeting of the Southeastern Section of the American Urological Association. *Urology Review Supplement: highlights from the sectional meetings of the American Urological Association. The American Journal of Urology Review*, 2(2): 6, 2004.
9. **Williams, C.R.**, Heaven, K.J., Joseph, D.B.: Testicular Torsion; Is There A Seasonal Predilection for Occurrence? *Urology*, 61(3): 638, 2003.
10. Miller, C.R., **Williams, C.R.**, Buchsbaum, D.J., Gillespie, G.Y. Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas. *Cancer Research*, 62: 773, 2002.
11. **Williams, C.R.**, Klemm, K. M., and Urban, D.A.: Cecal adenocarcinoma involving the bladder. *BJU International*, 89 (4cr): 466, 2002.
12. **Williams, C.R.**, Perez, L.M., and Joseph, D.B.: The accuracy of renal-bladder ultrasonography as a screening method to diagnose posterior urethral valves. *J. Urol.*, 165: 2245, 2001.
13. Bukowski, T.P. and **Williams, C.R.**: Percutaneous, intravesical retrieval of misplaced urethral stent: New laparoscopic instrumentation. *J. Urol.*, 157: 2257, 1997.
14. Willard, T.B., **Williams, C.**, Krishnan, R., and Carson, C.C.: Acucise endopyelotomy: A successful therapeutic intervention in the treatment of ureteropelvic junction obstruction. *Techniques in Urology*, 4(3): 118, 1998.

Textbook Chapters

1. **Williams, C.R.** and Pinto, P.P. Laparoscopic Partial Nephrectomy. In Bishoff, J.T. and Kavoussi, L.R. (eds). *Atlas of Laparoscopic Urology Surgery*. Elsevier. 2007.

CHRISTOPHER R. WILLIAMS, M.D.

Published abstracts

1. **Williams, C.R.**, Linehan, W.M., and Neckers, L. 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin administration results in cytostasis and decreased tyrosine phosphorylation in teratocarcinoma. Proceedings of the American Urological Association Annual Meeting, San Antonio, TX, 2005.
2. **Williams, C.R.**, Linehan, W.M., and Neckers, L. In vitro cytotoxicity of 17-DMAG in testicular teratoma. Proceedings of the American Association for Cancer Research, 2005.
3. **Williams, C.R.**, Neckers, L., Tabios, R., Linehan, W.M., and Coleman, J. Local and systemic cytostatic effects of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin in a xenograft bladder tumor model. Proceedings of the Society of Urologic Oncology Annual Meeting, Bethesda, MD, 2004.
4. **Williams, C.R.**, Neckers, L.M., Bottaro, D.P., Coleman, J. The HSP90 inhibitor 17-desmethoxy-17-N, N-dimethylaminoethylamino-geldanamycin (17-DMAG) downregulates expression of c-Met and Akt and phospho-Akt proteins in T24 bladder cancer cells. *J Urol*, 171(4): 258, Suppl. S APR 2004.
5. **Williams C.R.**, Miller C.R., Buchsbaum D.J. Uracil phosphoribosyltransferase potentiates 5-fluorouracil and cytosine deaminase/5-fluorocytosine cytotoxicity in prostate cancer. Proceedings of the American Association for Cancer Research. 42:2445 2001.
6. Miller C.R., Buchsbaum D.J., **Williams C.R.**, Kiss P., Elgavish G., Grizzle W.E., Diasio R.B., Johnson M.R., Gillespie G.Y. Cytosine deaminase/5-fluorocytosine therapy for gastrointestinal (GI) and non-GI malignancies. Proceedings of the American Association for Cancer Research. 42: 28, 2001.
7. Miller C.R., Kelly F.J., **Williams C.R.**, Curiel D.T., Buchsbaum D.J., Gillespie G.Y. A quantitative method for determining adenovirus gene transfer efficiency with established and primary human tumor cell cultures. *Molecular Therapy*. 3: S165, 2001.

POSTER EXHIBITS

1. **Williams, C.R.**, Linehan, W.M., and Neckers, L. 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin administration results in cytostasis and decreased tyrosine phosphorylation in teratocarcinoma. Presented at the 2005 meeting of the American Urologic Association.
2. **Williams, C.R.**, Linehan, W.M., and Neckers, L. In vitro cytotoxicity of 17-DMAG in testicular teratoma. Presented at the 2005 meeting of the American Association for Cancer Research.
3. **Williams, C.R.**, Neckers, L., Tabios, R., Linehan, W.M., and Coleman, J. Local and systemic cytostatic effects of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin in a xenograft bladder tumor model. Presented at the 2004 meeting of the Society of Urologic Oncology.

CHRISTOPHER R. WILLIAMS, M.D.

4. **Williams, C.R.**, Neckers, L.M., Bottaro, D.P., Coleman, J. The HSP90 inhibitor 17-desmethoxy-17-N, N-dimethylaminoethylamino-geldanamycin (17-DMAG) downregulates expression of c-Met and Akt and phospho-Akt proteins in T24 bladder cancer cells. Presented at the 2003 meeting of the Society of Urologic Oncology and the 2004 meeting of the American Urological Association. Published in *J Urol*, 171(4): 258, Suppl. S APR 2004.
5. **Williams C.R.**, Miller C.R., Buchsbaum D.J. Uracil phosphoribosyltransferase potentiates 5-fluorouracil and cytosine deaminase/5-fluorocytosine cytotoxicity in prostate cancer. Presented at the 2001 meeting of the American Association for Cancer Research.
6. Nielsen, A.N., Billings, B.J., **Williams, C.R.**, Joseph, D.B., and Perez, L.M. Posterior Urethral Valves: Preliminary study suggesting a higher incidence in African-Americans. Presented by Dr. Nielsen at the 2001 Southeastern Section of the American Urological Association Meeting.
7. **Williams, C.R.**, Perez, L.M., and Joseph, D.B. The accuracy of renal-bladder ultrasonography as a screening method to diagnose posterior urethral valves. Presented by David B. Joseph, M.D. at the 2000 International Meeting of the American Academy of Pediatrics in Paris, France.
8. Willard, T. B., **Williams, C.R.**, Krishnan, R., Benevides, M.D., and Carson, C.C. Acucise Endopyelotomy: Review of The UNC Experience. Presented by Marc Benevides at the 1998 World Endourology Meeting, September 1998.

ORAL PRESENTATIONS

1. **Williams, C. R.**, Linehan, W.M., Tabios, R., and Neckers, L. Intratumoral injection of 17AAG decreases tumor size and expression of HSP90 client proteins in prostate cancer xenograft model. Presented at the 2006 Southeastern Section of the American Urological Association Meeting in Puerto Rico.
2. **Williams C.R.**, Miller C.R., Buchsbaum D.J. Uracil phosphoribosyltransferase potentiates 5-fluorouracil and cytosine deaminase/5-fluorocytosine cytotoxicity in prostate cancer. Presented at the 2001 meeting of the National Medical Association in Nashville, TN.
3. **Williams, C.R.**, Klemm, K. M., and Urban, D.A. Cecal adenocarcinoma involving the bladder. Presented at the T. Leon Howard Pyelogram Program at the 2001 Southeastern Section of the American Urological Association Meeting in New Orleans, LA.
4. **Williams, C.R.**, Perez, L.M., and Joseph, D.B. The accuracy of renal-bladder ultrasonography as a screening method to diagnose posterior urethral valves. Presented at the 2000 meeting of the Southeastern Section of the American Urological Association and the 2000 meeting of the National Medical Association.

CHRISTOPHER R. WILLIAMS, M.D.

MEETINGS ATTENDED

1. National Urology Review. Chicago, IL. December 1999
2. Southeastern Section of the American Urological Association. Orlando, FL. March 2000; New Orleans, LA. March 2001; Savannah, GA. March 2003; Rio Grande, Puerto Rico. March 2006; Orlando, FL. March 2007
3. Urology Seminar. San Destin, FL. July 2000, July 2002
4. National Medical Association, Urologic Section. Washington, D.C. August 2000; Nashville, TN, August 2001
5. American Association for Cancer Research. New Orleans, LA. March 2001; Anaheim, CA. April 2005
6. American Urological Association. Anaheim, CA. June 2001; Orlando, FL. May 2002; San Francisco, CA. May 2004; San Antonio, TX. May 2005
7. AUA Summer Research Conference: New Directions in Renal Cell Carcinoma; Houston, TX. August 2002
8. Urologic Oncology: Extraordinary Opportunities for Discovery; Bethesda, MD. December 2002; 2003; 2004
Urologic Oncology: Advances in Clinical Practice; Houston, TX. October 2007

SPECIAL EXPERIENCES

1. International Volunteers in Urology Traveling Resident Scholarship Program; One week surgical mission in Peru, South America, fall 2001
2. Internship; University of Ghana Hospital, Accra - Ghana, West Africa; Observation of General Practice, Obstetrics and Gynecology, summer 1992
3. Publishing Internship; Sports Illustrated For Kids, New York, NY; Publishing assistant, summer 1991
4. Internship; Dallas Police Department, Dallas, TX; Civilian observer with Medical Examiner, Individual Precincts, Private Investigation and Helicopter Divisions, summer 1990
5. Internship; Department of Health and Human Services, Dallas, TX; Civilian observer with Restaurant Inspection, Swimming Pool Inspection and Environmental Safety Divisions, summer 1990
6. Pacific Crest Outward Bound Outdoor Leadership Program, Bend Oregon; 3-week survival course emphasizing character-building and interpersonal skills via whitewater rafting, hiking, and mountain and rock climbing, summer 1989